Form 4: NextCure Director David S. Kabakoff Acquires Stock Options
SEC Form 4 Filing
Director David S. Kabakoff acquired stock options in NextCure, Inc. on June 20, 2024.
Summary
- David S. Kabakoff, a director of NextCure, Inc., acquired 28,050 stock options on June 20, 2024.
- The exercise price of these options is $1.5.
- The options vest fully on the earlier of June 20, 2025, or the date of the 2025 Annual Meeting of Stockholders.
- The options expire on June 19, 2034.
- Following the transaction, Kabakoff directly owns 28,050 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard Form 4 filing indicating a director's acquisition of stock options, which can be interpreted as a sign of confidence, but it's not definitively positive or negative.
Positives
- The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 06/20/2024 | Date of the transaction: acquisition of stock options. |
| 06/20/2025 | Earliest vesting date for the stock options. |
| 06/19/2034 | Expiration date for the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.